Apheresis as emerging treatment option in severe early onset preeclampsia.

Apheresis as emerging treatment option in severe early onset preeclampsia. Atheroscler Suppl. 2019 Dec;40:61-67 Authors: Contini C, Pütz G, Pecks U, Winkler K Abstract Based on an early suggestion by Winkler et al. 2003 and a subsequent successful study by Wang et al. 2006 using lipid apheresis (LA) in 9 patients with preeclampsia to prolong pregnancies, the use of apheresis as therapeutic option in severe early onset preeclampsia has received increasing attention. Further studies using different LA systems also prolonged pregnancy and have been published in the last few years. Albeit using different LA systems and relying on different working hypothesis, all studies demonstrated a promising stabilisation against the disease's progression. Overall time from hospitalisation to the need for mandatory delivery was longer for those patients receiving apheresis compared to historical or matched control patients not receiving apheresis. These data will be reviewed and different hypotheses about the beneficial mechanism of action of apheresis will be discussed. Since up to now there is no curative treatment for preeclampsia other than observation and delivery, future work shall be encouraged. PMID: 31818451 [PubMed - in process]
Source: Atherosclerosis Supplements - Category: Cardiology Authors: Tags: Atheroscler Suppl Source Type: research